Introduction Omalizumab is a high-cost therapy recommended for the treatment of severe
allergic asthma. Objective To find clinical parameters that are related to the sustained …

Background Omalizumab is licensed as add-on therapy for patients with severe allergic
asthma. Response is in most studies scored by the physician's global evaluation of …

Objective. Several clinical studies have demonstrated the effectiveness of omalizumab in
patients with severe allergic asthma but the treatment period has always been relatively …

Introduction: Efficacy and safety of omalizumab in patients with severe allergic asthma has
been established in both randomized controlled trials and real-life studies Aim: To evaluate …

Results One hundred and fourteen patients from the Czech Republic were enrolled in the
eXpeRience registry. A total of 88.9% of the patients were evaluated as responders to …

Background: Omalizumab improves asthma control in patients with uncontrolled severe
allergic asthma; however, appropriate patient selection is crucial. Information in this field is …

BACKGROUND: Omalizumab is a monoclonal antibody indicated for treatment of severe
persistent allergic asthma inadequately controlled despite optimal controller therapy. We …

Background Omalizumab arose as a therapeutic option in patients suffering from moderate
to severe refractory allergic asthma. It acts as a humanized monoclonal antibody …

Introduction: Omalizumab is indicated for the treatment of severe allergic bronchial asthma
and chronic spontaneous urticaria, although number of studies confirmed the efficacy of this …

Aim: This subgroup analysis assessed the real-life effectiveness and safety of omalizumab
in Slovakian patients with severe allergic asthma enrolled in the eXpeRience registry …